2021
Use of Denosumab after Zoledronic Acid in Patients with Multiple Myeloma: Real-World Experience from 2015 to 2019 at Yale Cancer Center
Dosani T, Poteraj A, Parker T, Bar N, Browning S, Gorshein E, Anderson T, Insogna K, Neparidze N. Use of Denosumab after Zoledronic Acid in Patients with Multiple Myeloma: Real-World Experience from 2015 to 2019 at Yale Cancer Center. Blood 2021, 138: 4756. DOI: 10.1182/blood-2021-147466.Peer-Reviewed Original ResearchBone-modifying agentsUse of denosumabYale Cancer CenterZoledronic acidMultiple myelomaMM patientsCancer CenterMedian numberPhysician preferenceCommon reasonClinical practiceNew fracturesNuclear factor kappa-B ligandStudy periodApproval of denosumabEfficacy of denosumabIncidence of SREsMain treatment centreSmilow Cancer HospitalSuppress bone turnoverPatient's renal functionBone resorption markersCohort of patientsGlomerular filtration rateDate of diagnosis
2016
Immunologic Status Evaluated By the Absolute Lymphocyte/Monocyte Ratio Provides a Powerful Prognostic Tool for Newly Diagnosed Multiple Myeloma
Malek E, Dosani T, Pinto R, Covut F, Akabane H, Driscoll J, De Lima M. Immunologic Status Evaluated By the Absolute Lymphocyte/Monocyte Ratio Provides a Powerful Prognostic Tool for Newly Diagnosed Multiple Myeloma. Blood 2016, 128: 1862. DOI: 10.1182/blood.v128.22.1862.1862.Peer-Reviewed Original ResearchALC/AMC ratioLow ALC/AMC ratioProgression-free survivalAbsolute lymphocyte countAbsolute monocyte countTumor-associated macrophagesHigh absolute monocyte countLow absolute lymphocyte countHost immune statusOverall survivalPrognostic factorsMM patientsHost immune systemPrognostic significanceMultivariate analysisImmune statusSurrogate markerSuperior median progression-free survivalImmune systemPredictors of PFSLymphocyte/monocyte ratioMedian progression-free survivalLonger progression-free survivalDifferent progression-free survivalImmunosuppressive tumor-associated macrophages